<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="402">
  <stage>Registered</stage>
  <submitdate>16/10/2003</submitdate>
  <approvaldate>16/10/2003</approvaldate>
  <nctid>NCT00071279</nctid>
  <trial_identification>
    <studytitle>SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis</studytitle>
    <scientifictitle>The Van Gogh-extension Trial, a Multicenter, International, Randomized, Double-blind, Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous SR34006 With Placebo in the Long-term Prevention of Symptomatic Venous Thromboembolism in Patients With Symptomatic Pulmonary Embolism or Deep-vein Thrombosis Who Completed 6 Months of Treatment With Vitamin K Antagonist or SR34006</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>SR34006</secondaryid>
    <secondaryid>EFC5135</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pulmonary Embolism</healthcondition>
    <healthcondition>Deep Vein Thrombosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - SR34006 (idraparinux sodium) Injection

Treatment: drugs: SR34006 (idraparinux sodium) Injection


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Symptomatic recurrent PE/DVT during the 6-month study treatment period.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Major bleeding during the 6-month study treatment period.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients with confirmed symptomatic Pulmonary Embolism (PE) or Deep Vein Thrombosis
             (DVT) who have been treated with acenocoumarol, warfarin or SR34006 for six months

          -  Written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Legal age limitations (country specific)

          -  Indication for anticoagulation other than PE or DVT

          -  Creatinine clearance (CLcr) &lt;10 mL/min, severe hepatic disease, or bacterial
             endocarditis

          -  Participation in a pharmacotherapeutic study other than the Van Gogh-PE or DVT study
             within the prior 30 days

          -  Life expectancy &lt;3 months

          -  Patients in whom anticoagulation treatment for their index PE or DVT should be
             continued beyond 6 months

          -  Active bleeding or high risk for bleeding

          -  Uncontrolled hypertension: systolic blood pressure &gt;180 mm Hg or diastolic blood
             pressure &gt; 110 mm Hg

          -  Pregnancy, or childbearing potential without proper contraceptive measures, women who
             are breastfeeding.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1215</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2005</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Box Hill, Clayton, Coffs Harbour, Garran, Kogarah</hospital>
    <hospital> - Premantle, Redcliffe, St. Leonards, South Australia</hospital>
    <hospital> - Ringwood East, Woolloongabba</hospital>
    <postcode> - Box Hill, Clayton, Coffs Harbour, Garran, Kogarah</postcode>
    <postcode> - Premantle, Redcliffe, St. Leonards, South Australia</postcode>
    <postcode> - Ringwood East, Woolloongabba</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz, Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles, Duffel, Leuven, Lier, Zottegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre, Salvador, Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno, Hradec Karlove, Jihlava, Karlovy Vary, Kladno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Ostrava-Poruba, Plzen, Prague, Usti nad Labem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Arhus, Braedstrup, Frederiksberg, Glostrup, Hillerod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Kobenhavn, Odense</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Seinajoki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Besancon, Brest, Chambray les Tours, Clamart, Grenoble</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier, Paris, Rouen, Saint Brieuc, Saint Etienne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse, Valenciennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin, Bochum, Dresden, Heidelberg, Ibbenburen, Mannheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genova, Milano, Padova, Parma, Pavia, Piacenza, Reggio Emilia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Treviso, Venezia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Alkmaar, Almere, Amersfoort, Amsterdam, Arnhem, Haarlem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Maastricht, Nieuwegein, Sittard, Zwolle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo, Rud</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok, Szczecin, Warszawa, Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Bloemfontein, Bryanston, Durban</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona, Madrid, Torrelavega, Xativa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Goteborg, Jonkoping, Stockholm, Varnamo, Vastervik</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients diagnosed with pulmonary embolism (blood clot in the lung) or deep vein thrombosis
      (blood clot in a leg vein) are at risk for these blood clots to reoccur. Anticoagulant
      (blood-thinning) drugs are normally given immediately after the clot is discovered and are
      continued for a period of 3 or 6 months during which time the risk for recurrence is highest.
      Research has shown that when oral anticoagulants are used appropriately during this period,
      patients are less at risk for a recurrent blood clot and this risk reduction outweighs the
      potential for bleeding to occur.

      In this study, patients who had a blood clot in the lung or in a leg vein and completed 6
      months of treatment with daily oral vitamin K antagonists (acenocoumarol or warfarin) or
      once-weekly injections of SR34006 (a new anticoagulant drug) will receive an additional 6
      months of once-weekly SR34006 injections or injections of a solution containing no drug
      (placebo). This trial will evaluate whether patients treated for an additional 6 months with
      SR34006 have fewer recurrences of blood clots when compared to patients treated with placebo.

      Assignment to either SR34006 or placebo will be purely by chance. Neither the patients nor
      their doctors will know which treatment is being given.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00071279</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>ICD CSD</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>